Literature DB >> 25218393

Liprosomes loading paclitaxel for brain-targeting delivery by intravenous administration: in vitro characterization and in vivo evaluation.

Bo Tang1, Guihua Fang1, Ying Gao1, Yi Liu1, Jinwen Liu1, Meijuan Zou1, Gang Cheng2.   

Abstract

In this study, a lipid-protein nanocomplex (liprosome) was evaluated for its potential use for brain-targeting drug delivery. Liprosome was fabricated with the desolvation-ultrasonication method and characterized in terms of particle size, size distribution, zeta potential, morphology, crystal state of the drug, and in vitro release. The in vivo distribution of paclitaxel loading lipid-protein nanocomplex (PTX-liprosome) and Taxol were compared after i.v. administration in mice. The prepared PTX-liprosome has a high entrapment efficiency (>90%), small particle size (approximately 110 nm), and narrow distribution (P.I.<0.2). Transmission electron microscopy (TEM) indicated that liprosome had a spherical multilayer structure. X-ray photoelectron spectroscopy (XPS) showed that the conjugate of PTX and BSA was in the interior of the PTX-liprosome. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) demonstrated that the drug existed in a molecular or amorphous state. Fourier transform infrared spectroscopy (FTIR) suggested that the hydrophobic interactions, electrostatic interactions and hydrogen bonds among of the PTX, lipid and protein play an important role during the formation of the PTX-liprosome. The hemolysis test showed a good safety profile for the intravenous administration of liprosome. The result of the in vivo distribution suggested that liprosome increased the drug uptake by the brain tissue and decreased drug accumulation in non-target organs. Therefore, liprosome is a potential drug delivery system for transporting PTX to the brain.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain-targeting; Lipid–protein nanocomplex; Liprosome; PTX; Tissue distribution

Mesh:

Substances:

Year:  2014        PMID: 25218393     DOI: 10.1016/j.ijpharm.2014.09.011

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation.

Authors:  Soon-Seok Hong; Ju Yeon Choi; Jong Oh Kim; Mi-Kyung Lee; So Hee Kim; Soo-Jeong Lim
Journal:  Int J Nanomedicine       Date:  2016-09-06

2.  VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer.

Authors:  Bo Tang; Yu Qian; Yi Gou; Gang Cheng; Guihua Fang
Journal:  Molecules       Date:  2018-10-25       Impact factor: 4.411

3.  Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation.

Authors:  Na Qu; Yating Sun; Yujing Li; Fei Hao; Pengyu Qiu; Lesheng Teng; Jing Xie; Yin Gao
Journal:  Biomed Eng Online       Date:  2019-01-31       Impact factor: 2.819

4.  pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis.

Authors:  Huiru Zhu; Li Kong; Xu Zhu; Tingting Ran; Xiaojuan Ji
Journal:  Pharmaceutics       Date:  2022-02-27       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.